Answers are grounded in this paper and cite their sources.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Multiple pathways are involved in its pathophysiology, but the exact mechanisms are still unknown. In this study, we investigate the role of gamma-aminobutyric acid (GABA) in ALS and the related C9orf72 repeat expansion (C9). As the primary inhibitory neurotransmitter, GABA may affect hyperexcitability in ALS. Decreased GABA levels have been reported in the motor cortex in ALS, but neither regions outside the motor area nor carriers of ALS-related pathogenic genetic variants were investigated. We used GABA-edited magnetic resonance spectroscopy (MEGA-sLASER) at 7 T to examine ratios of GABA to creatine. We compared individuals with ALS (n = 17) to controls (n = 13) and separately compare asymptomatic C9orf72 repeat expansion carriers (n = 5) to non-carriers (n = 7) from a single family. We placed the voxel of interest in the parietal lobe as it is specifically at risk in C9 carriers. We found no statistically significant differences in mean GABA ratios in either comparison, but individuals with ALS showed a higher variance than controls (p = 0.026). We conclude that parietal GABA is not involved in ALS pathology in all individuals with ALS, but increased variance indicates heterogeneity and may reflect subgroups with GABAergic dysfunction.
No takes yet. Share an insight, caveat, or question.
Hoek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: